Simulations Plus, Inc. (SLP)
NASDAQ: SLP · Real-Time Price · USD
24.29
+0.09 (0.37%)
At close: Mar 28, 2025, 4:00 PM
25.16
+0.87 (3.58%)
After-hours: Mar 28, 2025, 6:25 PM EDT
Simulations Plus Market Cap
Simulations Plus has a market cap or net worth of $488.05 million as of March 28, 2025. Its market cap has decreased by -43.01% in one year.
Market Cap
488.05M
Enterprise Value
471.20M
1-Year Change
-43.01%
Ranking
Category
Stock Price
$24.29
Market Cap Chart
Since December 1, 1998, Simulations Plus's market cap has increased from $4.50M to $488.05M, an increase of 10,745.45%. That is a compound annual growth rate of 19.47%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Mar 28, 2025 | 488.00M | -12.81% |
Dec 31, 2024 | 559.70M | -37.27% |
Dec 29, 2023 | 892.20M | 20.19% |
Dec 30, 2022 | 742.30M | -22.11% |
Dec 31, 2021 | 953.00M | -33.52% |
Dec 31, 2020 | 1.43B | 179.82% |
Dec 31, 2019 | 512.30M | 47.76% |
Dec 31, 2018 | 346.70M | 24.58% |
Dec 29, 2017 | 278.30M | 67.45% |
Dec 30, 2016 | 166.20M | -1.31% |
Dec 31, 2015 | 168.40M | 49.69% |
Dec 31, 2014 | 112.50M | 38.89% |
Dec 31, 2013 | 81.00M | 15.88% |
Dec 31, 2012 | 69.90M | 50.00% |
Dec 30, 2011 | 46.60M | 11.75% |
Dec 31, 2010 | 41.70M | 93.95% |
Dec 31, 2009 | 21.50M | 42.38% |
Dec 31, 2008 | 15.10M | -75.25% |
Dec 31, 2007 | 61.00M | 42.86% |
Dec 29, 2006 | 42.70M | 125.93% |
Dec 30, 2005 | 18.90M | -5.03% |
Dec 31, 2004 | 19.90M | 28.39% |
Dec 31, 2003 | 15.50M | 89.02% |
Dec 31, 2002 | 8.20M | 182.76% |
Dec 31, 2001 | 2.90M | -57.35% |
View and export this data all the way back to 1998.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Eli Lilly and Company | 738.61B |
UnitedHealth Group | 472.03B |
Johnson & Johnson | 394.52B |
AbbVie | 363.15B |
Novo Nordisk | 305.46B |
AstraZeneca | 229.16B |
Abbott Laboratories | 226.88B |
Merck & Co. | 225.40B |